1	8 concomitant use of vigabatrin subject who take vigabatrin in the past must be discontinue for approximately 5 month prior to baseline and must have documentation show no evidence of a vigabatrin-associated clinically significant abnormality in an automate visual perimetry test|vigabatrin[21,31]|||||||5 month[110,117]||C0048044|14851|14851|vigabatrin
1	8 concomitant use of vigabatrin subject who take vigabatrin in the past must be discontinue for approximately 5 month prior to baseline and must have documentation show no evidence of a vigabatrin-associated clinically significant abnormality in an automate visual perimetry test|vigabatrin[49,59]|||||||||C0048044|14851|14851|vigabatrin
1	8 concomitant use of vigabatrin subject who take vigabatrin in the past must be discontinue for approximately 5 month prior to baseline and must have documentation show no evidence of a vigabatrin-associated clinically significant abnormality in an automate visual perimetry test|vigabatrin[186,196]|||||||||C0048044|14851|14851|vigabatrin
